Pharmacological Management of Coagulation

Correct Answer

B — Ticagrelor

Rationale

Ticagrelor is classified as a direct-acting, reversible P2Y12 receptor antagonist that binds an allosteric site on the receptor — a site distinct from the adenosine diphosphate binding site — and does not require hepatic metabolic activation to exert its antiplatelet effect. Clopidogrel and prasugrel are thienopyridine prodrugs that require cytochrome P450-mediated bioactivation and bind the P2Y12 receptor irreversibly. Cangrelor is also a direct-acting, reversible P2Y12 antagonist, but it is administered intravenously and has a very short offset of 60 to 90 minutes; it is not orally bioavailable.

Correct Answer

D — Prasugrel

Rationale

Prasugrel is classified as a third-generation thienopyridine prodrug with faster and more efficient bioactivation than clopidogrel, producing greater and less variable platelet inhibition. Unlike clopidogrel, whose conversion to its active metabolite is highly dependent on cytochrome P450 2C19 activity, prasugrel undergoes rapid intestinal esterase-mediated hydrolysis to an intermediate that then requires minimal cytochrome P450 2C19 conversion. This makes prasugrel's antiplatelet effect largely independent of CYP2C19 loss-of-function variants. Ticagrelor and cangrelor are direct-acting P2Y12 antagonists and are not thienopyridines. Clopidogrel is also a thienopyridine but is the second-generation agent with substantially greater CYP2C19 dependence.

Correct Answer

A — Cangrelor

Rationale

Cangrelor is the only intravenous P2Y12 receptor inhibitor currently in clinical use. It is a direct-acting (no prodrug activation required), reversible antagonist with a plasma half-life of approximately 3 to 6 minutes and a platelet function offset of 60 to 90 minutes after stopping the infusion. This rapid, predictable offset makes cangrelor the only agent available for perioperative P2Y12 inhibitor bridging when surgery must occur before oral agents can be safely resumed. Ticagrelor is a direct-acting reversible P2Y12 antagonist but is administered orally with a platelet function offset of 24 to 48 hours. Prasugrel and clopidogrel are oral thienopyridine prodrugs with irreversible binding and platelet function recovery over 5 to 10 days requiring new platelet turnover.

Correct Answer

A — Abciximab

Rationale

Abciximab is classified as a chimeric human-murine monoclonal antibody fragment (Fab) directed against the glycoprotein IIb/IIIa receptor. It binds with high affinity and functionally irreversible kinetics, producing prolonged platelet inhibition even after the infusion is stopped. Eptifibatide is a synthetic cyclic heptapeptide GP IIb/IIIa inhibitor, not an antibody fragment. Tirofiban is a non-peptide tyrosine derivative GP IIb/IIIa inhibitor. Vorapaxar is a protease-activated receptor 1 antagonist and does not target GP IIb/IIIa.

Correct Answer

B — Vorapaxar

Rationale

Vorapaxar is classified as a protease-activated receptor 1 antagonist, the first drug in this class approved for clinical use. Protease-activated receptor 1 is the principal thrombin receptor on human platelets; thrombin cleaves its extracellular tethered ligand to activate platelets through a mechanism independent of P2Y12 and cyclooxygenase-1. Vorapaxar binds protease-activated receptor 1 in a functionally irreversible manner, providing antiplatelet protection through a pathway not addressed by aspirin or P2Y12 inhibitors. Ticagrelor is a P2Y12 receptor antagonist. Dipyridamole inhibits phosphodiesterase and blocks adenosine reuptake. Cilostazol is a selective phosphodiesterase type 3 inhibitor.

Correct Answer

D — Cilostazol

Rationale

Cilostazol is classified as a selective phosphodiesterase type 3 inhibitor. By blocking phosphodiesterase type 3, it prevents degradation of cyclic adenosine monophosphate in both platelets and vascular smooth muscle cells. Elevated cyclic adenosine monophosphate in platelets inhibits their activation, while elevated cyclic adenosine monophosphate in vascular smooth muscle produces vasodilation. This dual antiplatelet and vasodilatory profile makes cilostazol effective for improving walking distance in intermittent claudication from peripheral arterial disease. Vorapaxar is a protease-activated receptor 1 antagonist. Dipyridamole inhibits phosphodiesterase and blocks adenosine reuptake, but is not selective for phosphodiesterase type 3 and is not indicated for intermittent claudication. Ticagrelor is a P2Y12 receptor antagonist.

Correct Answer

A — Loss-of-function variants reduce cytochrome P450 2C19 activity, impairing conversion of clopidogrel to its active thiol metabolite and producing inadequate P2Y12 receptor inhibition and insufficient platelet suppression after stent implantation

Rationale

Clopidogrel is an inactive prodrug requiring two-step cytochrome P450-mediated bioactivation; cytochrome P450 2C19 is the primary enzyme responsible for the second and rate-limiting step generating the active thiol metabolite. Patients carrying CYP2C19*2 or CYP2C19*3 loss-of-function alleles have reduced or absent cytochrome P450 2C19 activity, resulting in substantially lower exposure to the active metabolite. Less active metabolite means fewer P2Y12 receptors are irreversibly inhibited, leaving more receptors available to respond to adenosine diphosphate released at sites of platelet activation. After coronary stent implantation, where complete platelet suppression is required to prevent the catastrophic complication of stent thrombosis, this residual platelet reactivity substantially increases risk. The US Food and Drug Administration issued a boxed warning for clopidogrel regarding this interaction, recommending consideration of alternative antiplatelet agents in known poor metabolizers. The mechanism is reduced active metabolite production, not excessive inhibition, altered absorption, or reversible binding.

Correct Answer

C — Ticagrelor inhibits the equilibrative nucleoside transporter responsible for adenosine reuptake, raising local adenosine concentrations and stimulating pulmonary adenosine receptors to produce dyspnea

Rationale

In addition to its P2Y12 receptor antagonism, ticagrelor inhibits the equilibrative nucleoside transporter 1, which normally mediates cellular adenosine reuptake and limits extracellular adenosine concentrations. By blocking this transporter, ticagrelor raises local adenosine levels in tissues including the pulmonary circulation. Elevated adenosine stimulates adenosine receptors on pulmonary chemoreceptors and vagal afferents, producing a sensation of dyspnea. This effect is not associated with true bronchoconstriction, reduced peak expiratory flow, or impaired cardiac function, and typically does not require discontinuation unless the patient finds it intolerable. Dyspnea was reported in approximately 14% of ticagrelor patients versus approximately 8% of clopidogrel patients in the pivotal ticagrelor versus clopidogrel trial. The same adenosine reuptake inhibition explains ticagrelor's association with ventricular pauses on Holter monitoring. The mechanism is not related to cyclooxygenase inhibition, pulmonary vasoconstriction, or microaggregation.

Correct Answer

B — Prasugrel's greater degree of platelet inhibition produces net clinical harm in patients with prior stroke or transient ischemic attack, where excess intracranial hemorrhage risk outweighs any ischemic benefit

Rationale

In the pivotal prasugrel versus clopidogrel trial, prasugrel reduced ischemic events overall compared to clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention, but the pre-specified subgroup of patients with prior stroke or transient ischemic attack showed net clinical harm — the increased risk of intracranial hemorrhage with prasugrel's more potent platelet inhibition exceeded the ischemic benefit in this population. Patients with prior cerebrovascular disease have higher baseline intracranial hemorrhage risk because of underlying cerebrovascular pathology. The contraindication is pharmacodynamic rather than pharmacokinetic: it reflects prasugrel's greater antiplatelet potency producing an unfavorable bleeding-to-ischemic benefit ratio in this specific population. Prasugrel does not inhibit cytochrome P450 2C19, does not cross the blood-brain barrier to act on cerebrovascular receptors, and does not inhibit cyclooxygenase-2.

Correct Answer

D — Abciximab redistributes from the surface of circulating platelets back into plasma, where it binds glycoprotein IIb/IIIa receptors on the transfused platelets; this redistribution dilutes the drug across a larger platelet pool and reduces the degree of inhibition per platelet

Rationale

Although abciximab binds glycoprotein IIb/IIIa with very high affinity, a small fraction continuously exchanges between the receptor surface and the plasma compartment. In the absence of transfusion, this redistribution is invisible because the same pool of platelets recaptures released drug. When fresh platelets are transfused, they provide a large new pool of unoccupied glycoprotein IIb/IIIa receptors that avidly capture abciximab molecules released from saturated patient platelets. Over time, the fixed amount of abciximab in the system is distributed across a substantially larger total number of glycoprotein IIb/IIIa receptors, reducing the fractional occupancy per platelet below the threshold required to block aggregation. Platelet function returns to approximately 50% of baseline within 12 hours of stopping the infusion through this dilution mechanism even without transfusion, but transfusion accelerates this process. Abciximab is not metabolized by platelet enzymes, fibrinogen does not competitively displace it, and transfused platelets express identical glycoprotein IIb/IIIa isoforms.

Correct Answer

A — Eptifibatide is primarily renally eliminated, and reduced creatinine clearance causes drug accumulation to supratherapeutic plasma concentrations, increasing the risk of excessive platelet inhibition and bleeding

Rationale

Eptifibatide is a cyclic heptapeptide with a plasma half-life of approximately 2.5 hours under normal renal function, cleared primarily by renal excretion with approximately 50% eliminated renally as unchanged drug or active metabolites. When creatinine clearance falls to 10 to 50 milliliters per minute, reduced renal elimination causes eptifibatide to accumulate, raising plasma concentrations above the intended therapeutic range and increasing the risk of excessive glycoprotein IIb/IIIa inhibition and serious bleeding. The standard management is to reduce the infusion rate by 50% while maintaining the same bolus dose. Eptifibatide is contraindicated when creatinine clearance falls below 10 milliliters per minute or in dialysis patients, because drug clearance is too severely impaired to achieve safe dosing. Unlike abciximab, which does not require renal dose adjustment, eptifibatide's renal dependence is a clinically critical pharmacokinetic distinction. The mechanism is drug accumulation from reduced clearance, not receptor expression changes, altered protein binding, or prodrug activation.

Correct Answer

C — Drug binding to glycoprotein IIb/IIIa exposes neoepitopes on the receptor that are recognized by naturally occurring antibodies, triggering antibody-mediated platelet clearance and acute thrombocytopenia

Rationale

When a glycoprotein IIb/IIIa inhibitor binds to the receptor, it induces conformational changes that expose new antigenic epitopes — neoepitopes — that are not present on the unoccupied receptor. A small proportion of patients have naturally occurring antibodies (present before any prior drug exposure) or drug-dependent antibodies that recognize these drug-receptor neoepitopes. Antibody binding to drug-bound platelets triggers Fc receptor-mediated clearance by the reticuloendothelial system, producing rapid and sometimes profound thrombocytopenia within hours of first exposure. This distinguishes glycoprotein IIb/IIIa inhibitor-associated thrombocytopenia from heparin-induced thrombocytopenia, which requires a lag period of 5 to 14 days for antibody generation. Management requires immediate drug discontinuation, platelet count monitoring, and platelet transfusion if serious bleeding occurs. The mechanism is immune-mediated platelet destruction, not microembolism, complement activation, or bone marrow suppression.

Correct Answer

B — Cilostazol inhibits phosphodiesterase type 3 in cardiac myocytes, raising intracellular cyclic adenosine monophosphate and increasing cardiac inotropy and chronotropy — a class of pharmacological effect associated with increased mortality in chronic heart failure

Rationale

Phosphodiesterase type 3 is expressed in both platelets and cardiac myocytes. In platelets and vascular smooth muscle, cilostazol's phosphodiesterase type 3 inhibition raises cyclic adenosine monophosphate to produce antiplatelet and vasodilatory effects. In cardiac myocytes, the same mechanism raises intracellular cyclic adenosine monophosphate, activating protein kinase A signaling to increase calcium cycling and enhance both contractility (positive inotropy) and heart rate (positive chronotropy). Oral phosphodiesterase type 3 inhibitors — including milrinone and enoximone as well as cilostazol in this structural regard — have been consistently associated with increased mortality in clinical trials of chronic heart failure, attributed to arrhythmia promotion and adverse myocardial energetics. The contraindication applies to all heart failure severity classes, not only advanced disease. The mechanism is on-target phosphodiesterase type 3 inhibition in cardiomyocytes, not cyclooxygenase suppression, antiplatelet excess, or afterload reduction.

Correct Answer

D — Aspirin contributes disproportionately to gastrointestinal and mucosal bleeding in the maintenance phase while P2Y12 inhibition with ticagrelor provides the primary antiplatelet protection against stent thrombosis; dropping aspirin after the highest-risk period reduces bleeding without removing the more protective antiplatelet pathway

Rationale

Dual antiplatelet therapy is required in the first weeks to months after stenting because platelet activation through both the thromboxane A2 pathway (aspirin target) and the adenosine diphosphate-P2Y12 pathway (ticagrelor target) contributes to stent thrombosis risk during this critical period. In the maintenance phase after the acute post-stent window, evidence suggests that P2Y12 inhibition with ticagrelor provides the pharmacologically dominant protection against platelet-mediated thrombotic events, while aspirin's additional contribution to ischemic risk reduction diminishes relative to its independent contribution to gastrointestinal and mucosal bleeding through cyclooxygenase-1 inhibition in gastric mucosa. By removing aspirin at 3 months — once the highest-risk stent thrombosis window has passed — the TWILIGHT trial demonstrated that bleeding can be substantially reduced without a detectable increase in ischemic events, because ticagrelor alone maintains the therapeutically sufficient antiplatelet pathway. This was achieved without aspirin's additional mucosal toxicity. Ticagrelor does not take 3 months to reach full potency and aspirin does not generate prothrombotic prostanoids.

Correct Answer

C — Reassure the patient that ticagrelor-associated dyspnea is a recognized off-target effect of adenosine reuptake inhibition, does not indicate pulmonary or cardiac pathology, and typically resolves or becomes tolerable without discontinuation; only switch antiplatelet therapy if the symptom is intolerable

Rationale

Ticagrelor inhibits the equilibrative nucleoside transporter 1, elevating extracellular adenosine levels in the pulmonary circulation. This stimulates pulmonary adenosine receptors and vagal afferents, producing a sensation of dyspnea that is not associated with bronchoconstriction, reduced spirometry, impaired gas exchange, or cardiac dysfunction. The normal oxygen saturation, clear lung exam, and preserved ejection fraction in this patient are consistent with this benign off-target mechanism. Most patients experience mild to moderate dyspnea that diminishes over weeks and does not require drug discontinuation. The clinical approach is to confirm there is no cardiac or pulmonary cause, explain the mechanism to the patient, and continue ticagrelor unless the dyspnea is truly intolerable — in which case switching to clopidogrel or prasugrel is appropriate. Immediate discontinuation is not warranted based on dyspnea alone, particularly given this patient's recent stent placement where uninterrupted antiplatelet therapy is critical to prevent stent thrombosis. Adding a beta-agonist is ineffective because ticagrelor does not cause bronchoconstriction. Aspirin is not responsible for this symptom.

Correct Answer

A — Extended-release dipyridamole plus aspirin, which combines cyclooxygenase-1 inhibition with phosphodiesterase inhibition and adenosine reuptake blockade to inhibit platelet activation through two independent pathways

Rationale

The fixed-dose combination of extended-release dipyridamole and aspirin (Aggrenox) is guideline-preferred alongside clopidogrel monotherapy for secondary prevention after non-cardioembolic ischemic stroke or transient ischemic attack. Dipyridamole inhibits phosphodiesterase, raising platelet cyclic guanosine monophosphate, and also blocks adenosine reuptake, elevating local adenosine at the platelet surface; both effects inhibit platelet activation through mechanisms independent of the thromboxane A2 pathway that aspirin blocks. This complementary mechanism — two distinct antiplatelet pathways — provides a rationale for the combination's efficacy advantage over aspirin monotherapy demonstrated in randomized trials. The most common adverse effect of dipyridamole is headache from adenosine-mediated vasodilation. Ticagrelor plus aspirin has not been approved for non-cardioembolic stroke secondary prevention. Vorapaxar is absolutely contraindicated in patients with any history of stroke or transient ischemic attack due to excess intracranial hemorrhage risk. Prasugrel is also contraindicated in patients with prior stroke or transient ischemic attack.

Correct Answer

C — Stop the eptifibatide infusion immediately and monitor the platelet count; administer platelet transfusion if serious bleeding develops

Rationale

A platelet count falling to 28,000 within hours of starting a glycoprotein IIb/IIIa inhibitor is consistent with acute drug-induced thrombocytopenia, a recognized class effect. Drug binding to glycoprotein IIb/IIIa exposes neoepitopes that are recognized by naturally occurring antibodies; Fc receptor-mediated clearance of antibody-coated platelets follows rapidly. The correct response is immediate drug discontinuation — dose reduction is inadequate because the mechanism is immune-mediated and not concentration-dependent in the usual sense. After stopping the infusion, eptifibatide's short half-life means drug levels fall quickly and platelet counts typically recover within 4 to 8 hours without additional intervention. Platelet transfusion is reserved for serious or life-threatening bleeding, as transfused platelets will also be exposed to residual drug and antibodies, limiting their effectiveness. Unlike abciximab, where platelet transfusion leverages drug redistribution across a diluted receptor pool, platelet transfusion in eptifibatide-induced thrombocytopenia does not offer the same mechanistic benefit. Switching to abciximab is contraindicated — acute thrombocytopenia is a class-wide adverse effect of all glycoprotein IIb/IIIa inhibitors through the same neoepitope mechanism, and cross-reactivity of antibodies between agents has been reported. Adding heparin would increase bleeding risk without addressing the thrombocytopenia.

Correct Answer

B — Cilostazol inhibits phosphodiesterase type 3, raising cyclic adenosine monophosphate in vascular smooth muscle cells to produce peripheral arterial vasodilation and in platelets to reduce platelet activation, improving blood flow to ischemic limb muscle

Rationale

Cilostazol is a selective phosphodiesterase type 3 inhibitor. Phosphodiesterase type 3 degrades cyclic adenosine monophosphate in both vascular smooth muscle cells and platelets. By inhibiting this enzyme, cilostazol raises intracellular cyclic adenosine monophosphate in peripheral arterial smooth muscle, producing vasodilation of peripheral arteries and increasing blood flow to ischemic limb muscle during exercise. The same rise in platelet cyclic adenosine monophosphate independently inhibits platelet activation, reducing the prothrombotic contribution of platelet aggregation at atherosclerotic plaque sites. Together, these effects improve walking distance in patients with intermittent claudication from peripheral arterial disease. Cilostazol does not inhibit cyclooxygenase-1, does not block P2Y12 receptors, and does not act through adenosine reuptake inhibition — the adenosine reuptake mechanism is specific to ticagrelor.